Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to $48.5 million.

  • Heron Therapeutics' Other Accumulated Expenses rose 19.11% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 19.11%. This contributed to the annual value of $41.8 million for FY2024, which is 0.24% down from last year.
  • Per Heron Therapeutics' latest filing, its Other Accumulated Expenses stood at $48.5 million for Q3 2025, which was up 4.94% from $46.2 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other Accumulated Expenses registered a high of $52.4 million during Q2 2023, and its lowest value of $24.7 million during Q1 2021.
  • Its 3-year average for Other Accumulated Expenses is $44.1 million, with a median of $42.3 million in 2024.
  • In the last 5 years, Heron Therapeutics' Other Accumulated Expenses decreased by 23.68% in 2021 and then skyrocketed by 58.20% in 2023.
  • Over the past 5 years, Heron Therapeutics' Other Accumulated Expenses (Quarterly) stood at $25.9 million in 2021, then skyrocketed by 49.09% to $38.6 million in 2022, then increased by 8.57% to $41.9 million in 2023, then decreased by 0.24% to $41.8 million in 2024, then grew by 19.11% to $48.5 million in 2025.
  • Its last three reported values are $48.5 million in Q3 2025, $46.2 million for Q2 2025, and $47.4 million during Q1 2025.